Assenagon Asset Management S.A. Cuts Stake in Omnicell, Inc. (NASDAQ:OMCL)

Assenagon Asset Management S.A. lowered its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 36.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 381,152 shares of the company's stock after selling 218,776 shares during the quarter. Assenagon Asset Management S.A. owned about 0.83% of Omnicell worth $16,618,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in OMCL. Arizona State Retirement System raised its position in Omnicell by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company's stock worth $348,000 after purchasing an additional 357 shares during the period. Texas Permanent School Fund Corp raised its holdings in shares of Omnicell by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company's stock worth $1,158,000 after buying an additional 479 shares during the period. Diversified Trust Co raised its holdings in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company's stock worth $416,000 after buying an additional 494 shares during the period. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock worth $55,000 after acquiring an additional 553 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in Omnicell by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company's stock valued at $625,000 after acquiring an additional 600 shares during the period. Institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a research note on Saturday, October 19th. JPMorgan Chase & Co. lifted their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a "neutral" rating in a report on Friday, August 23rd. Wells Fargo & Company boosted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research report on Monday, October 14th. Bank of America raised their target price on shares of Omnicell from $34.00 to $44.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Finally, Benchmark reiterated a "buy" rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of "Moderate Buy" and an average price target of $41.33.

Omnicell Stock Up 0.7 %

Shares of OMCL traded up $0.27 during mid-day trading on Friday, hitting $39.50. The company's stock had a trading volume of 297,644 shares, compared to its average volume of 515,308. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -85.87, a PEG ratio of 45.31 and a beta of 0.83. The company's 50-day moving average is $43.04 and its 200-day moving average is $34.71. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $45.84.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The business had revenue of $276.80 million for the quarter, compared to analysts' expectations of $254.41 million. During the same quarter last year, the firm earned $0.29 EPS. The business's revenue for the quarter was down 7.4% on a year-over-year basis. On average, equities research analysts forecast that Omnicell, Inc. will post 0.64 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.